Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023–2038.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO) [ Internet]. Geneve; 2020. Available from: https://www.who.int/chp/topics/rheumatic/en/
   Google Scholar
• Brazil. Ministry of Health. Approves the clinical protocol and therapeutic guidelines for rheumatoid arthritis and juvenile idiopathic arthritis [Internet]. Brasília; 2020. Available from: https://www.saude.gov.br/images/pdf/2020/marco/20/Portaria-Conjunta-PCDT-Artrite-Reumatoide-e-AIJ-20.03.2020.pdf
   Google Scholar
• Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014 Jan;73(1):3–5.
   PubMed Web of Science ®Google Scholar
• Gomes RKS, Pires FA, Nobre MRC, et al. Impacto da artrite reumatoide no sistema público de saúde em Santa Catarina, Brasil: análise descritiva e de tendência temporal de 1996 a 2009. Rev Bras Reumatol. 2017;57(3):204–209.
   Google Scholar
• Dos Santos JBR, Guerra Junior AA, da Silva MRR, et al. First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert Rev Clin Pharmacol. 2019;12(4):363–370.
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of Health. National policy on health technology management [Internet]. Brasília; 2020. Available from: bvsms.saude.gov.br/bvs/publicacoes/politica_nacional_gestao_tecnologias_saude.pdf
   Google Scholar
• Dos Santos JBR. Use of biological drugs for the treatment of rheumatoid arthritis in the unified health system: an epidemiological and economic analysis [thesis]. Belo Horizonte (MG): Universidade Federal de Minas Gerais; 2019.
   Google Scholar
• Junior AAG, Pereira RG, Gurgel EI, et al. Building the national database of health centred on the individual: administrative and epidemiological record linkage - Brazil, 2000–2015. Int J Popul Data Sci. 2018 Nov;3:20.
   Google Scholar
• Buendgens FB, Blatt CR, Marasciulo ACE, et al. Cost analysis of treatment for severe rheumatoid arthritis in a city in southern Brazil. Cad Saúde Pública. 2013;29:S81–S91.
   PubMed Web of Science ®Google Scholar
• da Silva MRR, Dos Santos JBR, Almeida AM, et al. Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. Expert Rev Clin Immunol. 2019 Aug;15(8):879–887.
   PubMed Web of Science ®Google Scholar
• Acurcio FA, Machado MA, Moura CS, et al. Medication persistence of disease-modifying antirheumatic drugs and anti-tumor necrosis factor agents in a cohort of patients with rheumatoid arthritis in Brazil. Arthritis Care Res (Hoboken). 2016 Oct;68(10):1489–1496.
   PubMed Web of Science ®Google Scholar
• Strand V, Miller P, Williams SA, et al. Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the corrona RA registry. Rheumatol Ther. 2017 Dec;4(2):489–502.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(39):S100–S108.
   PubMedGoogle Scholar
• Singh H, Kumar H, Handa R, et al. Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: an Indian experience. Arthritis. 2011;2011:146398.
   PubMedGoogle Scholar
• Klarenbeek NB, Koevoets R, van der Heijde DM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis. 2011 Oct;70(10):1815–1821.
   PubMed Web of Science ®Google Scholar
• Brazilian Institute of Geography and Statistics [Internet]. Statistics. Social. Population; 2020. Available from: https://www.ibge.gov.br/estatisticas/sociais/populacao/9126-tabuas-completas-de-mortalidade.html?=&t=o-que-e
   Google Scholar
• Ferreira PL, Ferreira LN, Pereira LN. Contribution for the validation of the Portuguese version of EQ-5D. Acta Med Port. 2013 Nov-Dec;26(6):664–675.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208.
   PubMed Web of Science ®Google Scholar
• Ribeiro RA, Neyeloff JL, Itria A, et al. Methodological guidelines for economic evaluation studies of health technologies in Brazil. J Bras Econ Saúde. 2016;8(3):174–184.
   Google Scholar
• Edlin R, McCabe C, Hulme C, et al. Effectiveness modelling for health technology assessment: a practical course. Switzerland: Springer; 2015. DOI:https://doi.org/10.1007/978-3-319-15744-3.
   Google Scholar
• Riveros BS, Rosim M, Ogata Pedro G, et al. Cost-effectiveness analysis and sensitivity analysis, a guide for a probabilistic approach: introduction to probabilistic sensitivity analysis (Part I). J Assist Farmac Farmacoecon. 2016 Sep;1(2):33–36.
   Google Scholar
• Brazilian Institute of Geography and Statistics (IBGE). Gross domestic product – GDP [Internet]. Brasília; 2020. Available from: https://www.ibge.gov.br/explica/pib.php
   Google Scholar
• Muszbek N, Proudfoot C, Fournier M, et al. Economic evaluation of sarilumab in the treatment of adult patients with moderately-to-severely active rheumatoid arthritis who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. Adv Ther. 2019 Apr;36(6):1337–1357.
   PubMed Web of Science ®Google Scholar
• Boyadzieva VV, Stoilov N, Stoilov RM, et al. Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. Front Pharmacol. 2018;9:794.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Chastek B, Becker L, et al. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population. J Manag Care Spec Pharm. 2015;21(4):318–329.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Johnson BH, Princic N, et al. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. J Med Econ. 2015;18(5):376–389.
   PubMed Web of Science ®Google Scholar